Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Analog Scaffolds: New Definition May Aid Medicinal Chemistry

By Future Science Group | November 9, 2016

Analog series-based scaffolds: a new definition that may aid medicinal chemistry.

While the Bemis-Murcko approach to scaffold analysis has remained the go-to definition for computational medicinal chemistry for the past few decades, it is not without its shortcomings.

New research published in Future Science OA from Jürgen Bajorath and colleagues at the University of Bonn (Germany) has presented a new scaffold definition, termed analog series-based scaffolds (ASB), and provides a free source of 12,294 scaffolds extracted from bioactive compounds.

“Revising the way molecular core structures (scaffolds) are defined for the systematic analysis of compound diversity and structure-activity relationships as well as for compound design has for [a] long [time] been on our agenda,” noted Bajorath. “Medicinal chemistry will likely benefit from a computationally consistently applicable scaffold definition that is based on compound series and takes reaction criteria into account. To these ends, the ASB scaffold formalism was developed.”

Describing the method, the authors explained: “From bioactive compounds, all analog series are isolated and for each series, ‘structural key’ compounds are identified. From each structural key compound, all matched molecular pair cores are derived. A core representing all analog relationships within a series principally qualifies as an ASB scaffold.”

When comparing ASB versus Bemis-Murcko scaffolds, the researchers demonstrated that the analyzed compounds contained the same Bemis-Murcko scaffold, yet for each series with a different target, a different ASB scaffold was obtained. However, for series with a single target, five Bemis-Murcko scaffolds were obtained and only a single ASB scaffold.

In the future, the group expects that further extensions of this approach could be considered, such as selection of multiple qualifying cores for a series, or the combination of structural information where no qualifying core is available.

Founded in 2001, Future Science Group is focused on breakthrough medical, biotechnological, and scientific research. www.futuresciencegroup.com.

(Source: EurekAlert!)


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50